安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- LABEL - Food and Drug Administration
VENCLEXTA is a BCL-2 inhibitor indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion, as detected by an FDA approved test, who have received at least
- VENCLEXTA® (venetoclax tablets): CLL SLL and AML Treatment
Discover VENCLEXTA® (venetoclax tablets): An oral therapy to help you fight certain blood cancers See full Prescribing and Safety information
- Venclexta: Package Insert Prescribing Information MOA
VENCLEXTA is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
- Venclexta (AbbVie Inc. ): FDA Package Insert - MedLibrary. org
VENCLEXTA is indicated in combination with azacitidine, or decitabine, or low-dose cytarabine for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy
- VENCLEXTA. VENCLEXTA - RxAbbVie
VENCLEXTA is indicated in combination with azacitidine, or decitabine, or low-dose cytarabine for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy
- AbbVie Inc. VENCLEXTA- venetoclax tablet, film coated
Instruct patients to take VENCLEXTA tablets with a meal and water at approximately the same time each day
- VENCLEXTA- venetoclax VENCLEXTA- venetoclax tablet, film coated AbbVie Inc.
Concomitant use of VENCLEXTA with P-gp inhibitors or strong or moderate CYP3A inhibitors increases venetoclax exposure, which may increase the risk of TLS at initiation and during the ramp-up phase of VENCLEXTA
- VENCLEXTA® (venetoclax tablets) AML CLL SLL Treatment HCP Site
Select a VENCLEXTA® indication VENCLEXTA is an oral therapy for select AML, CLL and SLL patients See full safety and Prescribing Information for more details
|
|
|